Tag: Covid

Categories
Health

2 folks had extreme allergic reactions after getting Covid vaccine

2 people had severe allergic reactions after getting Covid vaccine

Empty vials containing a dose of the Johnson & Johnson vaccine against the COVID-19 coronavirus lie on a table as South Africa resumes its vaccination campaign at Klerksdorp Hospital on February 18, 2021.

Phill Magakoe | AFP | Getty Images

Two study participants suffered severe allergic reactions shortly after receiving the Covid-19 vaccine from Johnson & Johnson, a J&J scientist told an FDA panel on Friday.

J&J was first briefed on the allergic reactions on Wednesday, Macaya Douoguih, director of clinical development and medical affairs for the vaccines division at J&J, Janssen, told the FDA’s Advisory Committee on Vaccines and Related Biological Products.

One of the people took part in an ongoing study in South Africa and developed anaphylaxis, a severe and life-threatening allergic reaction, after receiving the vaccine.

She did not provide details on the second person’s reaction.

“We will continue to monitor these events closely,” she told the panel.

To date, there have been no reports of anaphylaxis in J & J’s clinical study. The Centers for Disease Control and Prevention is currently overseeing events such as the introduction of Pfizer and Moderna vaccines by states and pharmacies.

There were 46 reports of anaphylaxis in patients who received Pfizer’s vaccine and 16 cases in patients who received Moderna’s vaccine, according to a CDC report released on February 16. The agency said the incidence of the reaction is within the range of cases reported for the influenza vaccine.

The CDC urges healthcare providers to monitor patients for 15 minutes after vaccination and for 30 minutes for patients with a history of allergic reactions.

If someone has a severe allergic reaction after the first dose of the Covid-19 vaccine, the CDC recommends not receiving the second dose, even if the allergic reaction wasn’t severe enough to require emergency care.

Categories
Business

J&J board member says 20 million Covid vaccine doses might be delivered by the tip of March

These are the most common side effects from J&J's

According to Dr. Johnson & Johnson board member Mark McClellan expects the company to have 20 million doses by the end of March as the US is just one step away from adding a third safe and effective vaccine to its arsenal.

“There will be a ramp-up, so 4 million doses are expected next week, rising in March, with 20 million doses dispensed by the end of March,” the former FDA commissioner said in an interview Friday night on The News with Shepard Smith. ” “So that’s 20 million people who are fully vaccinated because it’s just one dose of the vaccine.”

A panel of advisors to the Food and Drug Administration unanimously voted late Friday to recommend Johnson & Johnson’s single-dose shot for approval for emergency use. The FDA will decide on Saturday whether the vaccine will be approved. A recommendation from advisors to the Centers for Disease Control and Prevention would enable three to four million doses to be delivered next week.

McClellan told The News with Shepard Smith that the addition of the J&J vaccine will take the US a big step forward in fighting the coronavirus pandemic and protecting millions of people from the virus.

“That comes on top of some additions to the Pfizer and Moderna vaccine offering. They expect almost 90 million, 100 million doses … it’s a two-dose vaccine, but it all adds up to that we can get this far. ” At least 100 million people here in the US had been vaccinated by the end of March, “said McClellan, a health policy expert at Duke University.

Nationwide, average daily cases, hospitalizations and deaths have been going down for weeks, but Rochelle Walensky, director of the Centers for Disease Control and Prevention, said recent declines could flatten out.

“We may be through with the virus, but the virus clearly isn’t through with us,” Walensky said. “We cannot take it easy or give in to a false sense of security that the worst pandemic is behind us. Not now, not when mass vaccination is so close.”

The CDC director added that we may begin to see the effects of the new, contagious variants of Covid that are spreading across the country. McClellan agreed with Walensky, warning that “we should be concerned” when it comes to the new variants, but doubled the importance of vaccinations.

“The good news is that the vaccines offer really strong protection against the variants. The best way to contain the variants is to get as many people as possible vaccinated as soon as possible,” said McClellan.

Categories
Health

Biden administration faucets personal firms, enterprise teams for assist in Covid struggle

Biden administration taps private companies, business groups for help in Covid fight

United States President Joe Biden speaks about the 50 million doses of the Covid-19 vaccine administered in the United States during a landmark event in the Eisenhower Executive Office Building in Washington, DC on February 25, 2021.

Saul Loeb | AFP | Getty Images

On Friday, White House officials will unveil a new partnership between the administration and senior business groups to help with the national Covid-19 response and vaccine roll out, said Andy Slavitt, White House Senior Advisor on Covid Response, known.

The partnership includes the Chamber of Commerce, the Business Roundtable, the National Association of Manufacturers, and executives at Hispanic, African-American, Asian-American and other minority companies, Slavitt said.

The purpose of the partnership, a White House official told CNBC, is to urge businesses of all sizes to “promote public health actions to remove barriers to vaccination for employees and public health reporting related to masking.” and to improve vaccinations for their clients and communities. “The New York Times previously reported on the partnership.

Outside of the partnership, Walgreens and Uber are starting a pilot program to offer pharmacies free rides to get the Covid-19 vaccine. Other companies like Dollar General, Best Buy, and Target have announced that they will provide paid time off to compensate their employees for the vaccine.

Slavitt added that Lyft is partnering with CVS and the YMCA has also teamed up to offer 60 million free or discounted trips to help people get vaccinated. And Ford and The Gap have vowed to donate more than 100 million masks for free distribution.

“I wouldn’t portray these as a federal effort,” Slavitt said. “I would portray this as efforts by organizations across the country that we encourage others to take stock of in some cases.”

The White House, with its new business partners, will push more companies to do the same, Slavitt said.

Slavitt said administrative officials would be making calls to corporate groups over the next few weeks asking them to help with the federal response to the pandemic. He said the White House will urge them to oblige staff to follow public health precautions and educate the public about the importance of vaccination.

“First, masking and social distancing must be required to protect workers, customers, and others on the premises,” Slavitt said. Second, reduce barriers to vaccination. Make a plan to vaccinate employees and make it easier for employees to vaccinate by providing incentives such as paid time off or compensation for employees who get vaccinated when they attend Row are. “

Jay Timmons, president and CEO of the National Association of Manufacturers, said “no American is safe from COVID-19 until all Americans are safe,” said a statement. The group represents more than 12 million employees and 130,000 companies. “Manufacturers are proud to join the Biden administration in this call to arms.” He said the group and its members are determined to help end the pandemic.

Categories
Business

Biden Covid workforce holds press briefing as U.S. each day instances start to degree off

Biden Covid team holds press briefing as U.S. daily cases begin to level off

[The stream is slated to start at 11:00 a.m. ET. Please refresh the page if you do not see a player above at that time.]

President Joe Biden’s Covid-19 Response Team plans to hold a press conference on Friday at which officials will announce a new partnership with top corporate groups to help with the national pandemic response, a senior administrative official told CNBC.

The aim of the partnership is to encourage businesses of all sizes to “promote public health actions to remove barriers to vaccination for employees and improve public health reporting on masking and vaccination for their customers and communities”, the official told CNBC. The New York Times previously reported on the partnership

The press conference is taking place as the US reports a slight plateau in nationwide Covid-19 cases. According to a CNBC analysis of data compiled by Johns Hopkins University, the nation currently reports a weekly average of around 73,376 new cases per day, a slight increase compared to a week ago. The US hit a high of nearly 250,000 cases per day in early January after the winter break.

Biden’s top health officials warn that new, highly communicable variants of the coronavirus, particularly strain B.1.1.7 first identified in the UK, could delay the nation’s control of the pandemic.

– CNBC’s Will Feuer contributed to this report.

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

Categories
Health

Moderna strikes ahead to extend Covid vaccine provide in every vial

Moderna moves forward to increase Covid vaccine supply in each vial

A detail of the Moderna COVID-19 vaccine.

Allen J. Cockroaches | Los Angeles Times | Getty Images

Moderna said Monday it had “positive feedback” from the Food and Drug Administration on its proposal to increase the number of Covid-19 vaccine doses in each of its vials.

One vial of Moderna’s two-shot vaccine contains ten doses, enough to vaccinate five people, according to the Centers for Disease Control and Prevention. CNBC reported last month that Moderna had asked the FDA for permission to fill their Covid-19 vaccine bottles with up to five extra doses to remove a manufacturing bottleneck.

In a prepared statement filed ahead of a House hearing on Tuesday, Stephen Hoge, President of Moderna, said the US agency had “given the company positive feedback on our proposal and we are pursuing a plan that will keep the withdrawal up.” allows up to 15 doses from each vial. “

“That way we can produce and deliver more cans faster,” Hoge told the House Energy and Commerce Committee’s Oversight and Investigation Subcommittee. “We will continue to work with our manufacturing partners and the federal government to increase the efficiency of our production process without.” Impairment of quality or safety. “

The announcement comes as President Joe Biden tries to accelerate the pace of vaccinations in the US after a slower-than-expected rollout under former President Donald Trump and states are complaining that they are running out of doses.

Biden announced on Feb. 11 that his government had signed contracts with Pfizer and Moderna for an additional 200 million doses of Covid-19 vaccine, bringing the US number to 600 million. Since both approved vaccines require two doses three to four weeks apart, a total of 600 million doses would be enough to vaccinate 300 million people. The Biden government expects all of this to happen by the end of July.

It is unclear whether Moderna expects to be able to dispense 300 million doses by the end of July due to the increase in the doses per vial.

In December, the FDA announced that healthcare providers could use additional doses from vials of Pfizer’s Covid-19 vaccine. These vials are said to contain five doses, but some vendors have been able to extract a sixth or even a seventh dose. As with Pfizer, some vendors were able to use special syringes to obtain an additional dose of the Moderna vaccine.

Categories
Health

CDC examine finds nursing dwelling residents have been reinfected with worse case of Covid

CDC study finds nursing home residents were reinfected with worse case of Covid

A general overview of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta.

Tami Chappell | Reuters

A new CDC study found that some elderly people who appeared to have recovered from the coronavirus later had a second, even worse case – suggesting that asymptomatic or mild cases may not offer much protection against re-infection with Covid- 19 offer.

The study, published Thursday in the Centers for Disease Control and Prevention’s Weekly Report on Morbidity and Mortality, looked at two separate outbreaks that occurred three months apart in a qualified care facility in Kentucky. According to the study, 20 residents and five health care workers tested positive for the virus between mid-July and mid-August.

The second outbreak, between late October and early December, was worse: 85 residents and 43 healthcare workers tested positive for the virus. Among residents who tested positive during the first outbreak and were still living at the facility, five tested positive a second time more than 90 days after their first positive test.

Although Covid-19 reinfections do occur, they are generally rare.

Through frequent monitoring after the initial outbreak, all five residents had at least four negative tests between outbreaks, suggesting that they may have been re-infected with the virus later. Reinfection means that a person who had Covid-19 recovered and then got it again, according to the CDC.

“The history of exposure, including when the roommate infections occurred and symptoms recurred during the second outbreak, suggests that the second positive RT-PCR results represented new infections after the patients appeared to clear the first infection,” wrote Alyson Cavanaugh , one of the researchers who led the study.

While only two of the five residents showed mild symptoms during the first outbreak, all five potentially reinfected residents showed signs of illness the second time. The two residents who reported symptoms during the first outbreak “experienced more severe symptoms during the second infectious episode, according to the study.” One resident was hospitalized and subsequently died.

According to the study’s researchers, this was “noteworthy” as it suggests the possibility that people who show mild to no symptoms when they first become infected are “not creating a sufficiently robust immune response to prevent re-infection”. The results “suggest the possibility that the disease may be more severe during a second infection.”

“The results of this study underscore the importance of maintaining public health mitigation and protection strategies that reduce the risk of transmission, even in those with a history of COVID-19 infection,” wrote Cavanaugh.

Some limitations were noted in the study. Because the samples were not stored, the researchers were unable to perform genome sequencing, a laboratory technique that breaks down the virus’ genetic code to confirm re-infection. “There are no additional test results to prove the initial test result is really positive,” they said during the initial outbreak.

It is believed that the risk of re-infection for the general population is still low, but nursing home residents may be particularly at risk due to their coexistence and high number of exposures, according to the study.

“Qualified care facilities should employ strategies to reduce the risk of SARS-CoV-2 transmission in all residents, including those previously diagnosed with COVID-19,” Cavanaugh wrote.

Categories
Health

Dr. Scott Gottlieb on Pfizer’s efforts on a 3rd Covid vaccine shot

Dr. Scott Gottlieb on Pfizer's efforts on a third Covid vaccine shot

Pfizer board member Dr. Scott Gottlieb told CNBC on Thursday that the company is researching two different methods to provide vaccination protection against new coronavirus variants.

In an interview on Squawk Box, Gottlieb said the first approach focused on whether a booster shot using the current formulation of the two-dose vaccine would provide additional defense. Pfizer and its German partner BioNTech announced a test that was not examined until early Thursday.

“There is reason to believe that just boosting the existing vaccine against these new variants will give you extra protection,” said Gottlieb, a former Food and Drug Administration commissioner in the Trump administration.

The second endeavor is to modify the existing vaccine so that stronger immunity to virus mutations can be achieved, explained Gottlieb. The companies announced in a press release on Thursday that they are discussing the launch of this research study with regulators.

While new coronavirus variants affect public health officials, particularly the contagious strain first found in South Africa, Gottlieb said any change to the vaccine formulation would offer broad protection.

“What you want to do is not necessarily develop a vaccine that is specifically against [B.1.351], the change we’ve seen in South Africa, “said Gottlieb, who headed the FDA from 2017-2019.” You want to develop a protein sequence that is sort of a consensus sequence and that incorporates enough of the changes we’ve seen around the world that you have a vaccine that protects no matter what the virus does against itself. “

It is widely believed that the virus variant discovered in South Africa poses a greater challenge to existing vaccines than other new strains, such as the one originally discovered in the UK

For example, Johnson & Johnson reported that their vaccine was 72% effective in preventing symptomatic Covid in the US and 57% in South Africa, where the B.1.351 strain dominates. However, the vaccine provided 85% protection against severe Covid throughout the trial. Part of this has also been carried out in regions of Latin America where different variants exist.

The U.S. FDA is expected to use J & J’s vaccine soon after the agency’s emergency vaccine board meeting scheduled for Friday.

Pfizer-BioNTech and Moderna vaccines, which already have an emergency approval in the US, were tested in large phase three studies before the new variants were discovered. However, Pfizer and BioNTech conducted a study examining the variant found in South Africa. This indicated some reduction in antibody production, even though the vaccine was still neutralizing the virus.

In addition, Moderna has said that its two-dose vaccine appears to produce a weaker immune response against the South African variant, while adding that the antibody response remains at levels believed to provide protection.

Moderna announced Wednesday that it has shipped an optimized version of its vaccine to the National Institutes of Health to start various studies on variant protection. Similar to Pfizer, the company will also be testing a lower-dose booster shot of its current two-dose formulation.

Limited available doses have been a barrier to covid shots being given to more people once government approval has been granted. In the U.S. in particular, that situation has improved as companies ramp up production, and Gottlieb noted that J & J’s possible approval of the single-dose vaccine will also help expand access.

Should a booster shot be needed to ensure better protection against variants, Gottlieb was confident that the dosage might be available. “I don’t think we have to ration supplies if we want to give people a third booster in the fall,” he said.

“The challenge will be to think about the new vaccine variant and whether and when you would switch to this vaccine and how much you would produce,” said Gottlieb. “That will be a decision you need to make before these new variants of vaccines are likely to get approved. You may not want to switch all of your manufacturing, but you want to switch some of it.” He added, “You will likely have to make that decision sometime this summer.”

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, genetic testing startup Tempus, healthcare technology company Aetion, and biotech company Illumina. He is also co-chair of the Healthy Sail Panel of Norwegian Cruise Line Holdings and Royal Caribbean.

Categories
Health

Covid variants might ‘undermine all of our efforts’

CDC director warns strains could reverse drop in cases, hospitalizations

Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention.

Chip Somodevilla | Getty Images

New, highly transmissible variants of Covid-19 “may” “reverse” the nation’s control of the pandemic and could undermine “all of our efforts” against the disease if the virus proliferates in different parts of the world, Chief of the United States Centers for Disease Control and Prevention said on Wednesday.

Senior U.S. health officials have warned in recent weeks that the emergence of highly contagious variants, particularly of strain B.1.1.7 from the UK, could reverse the current downward trend in infections in the U.S. and delay the nation’s recovery from the pandemic.

The problem is not limited to the United States. As the coronavirus spreads, it makes large numbers of copies of itself, and each version is a little different from the previous one, experts say. The more people become infected, the more likely it is that problematic mutations will occur.

“Even if you weren’t necessarily inclined to be part of the global health effort, we have to, as any effort we are making here in this nation could potentially be undermined immediately from these variants,” said CDC Director Dr . Rochelle Walensky on Wednesday told the National Academy of Medicine and the American Public Health Association.

Scientists are not surprised by the emergence of the variants, and have repeated that the vaccines currently available should continue to work against them, although they may not be as effective as against the original “wild” strain.

Moderna announced Wednesday that it was shipping cans of a booster shot specifically targeting the variant common in South Africa known as the B.1.351 strain to the National Institutes of Health.

“We know this virus knows no geographic boundaries and that with the rapid spread of Covid-19 variants that can reverse advances in fighting this pandemic, it is more urgent than ever to address this reality,” said Walensky .

The US reports a weekly average of around 71,562 new Covid-19 cases per day, a 12% decrease from the previous week, and a significant decrease from the average of new cases in the US in early January of nearly 250,000 cases per day, according to a CNBC Analysis of data compiled by Johns Hopkins University.

Although not every country reports similar declines, global Covid-19 cases in the United States have declined for six consecutive weeks, according to the latest World Health Organization situation report released on Tuesday.

The decline is welcome news as countries battle to get their starting doses of Covid-19 vaccines. While some nations have been administering vaccines since December, some are just getting their first shots.

The first shipment of vaccines delivered under the World Health Organization’s COVAX program arrived in Ghana on Wednesday. Some experts have previously said that an equitable distribution of vaccines may be too late as wealthier nations have made their own deals with vaccine manufacturers and claimed their initial dose supply.

“The Covid-19 pandemic is a clear reminder of how closely we are connected as a global community,” said Walensky.

– CNBC’s Berkeley Lovelace Jr. and Natasha Turak contributed to this report.

Categories
Business

U.S. ought to push to get extra folks vaccinated earlier than Covid variants unfold, physician says

U.S. should push to get more people vaccinated before Covid variants spread, doctor says

Dr. Peter Hotez told CNBC’s “The News with Shepard Smith” that people in the US shouldn’t get complacent about dropping Covid cases, especially in the face of new reports of a new variant, B.1.526, hitting New York spread.

“We’re all running high because the numbers are falling, and I say we are in the eye of the hurricane and the next big wave is coming,” said Hotez, co-director of the vaccine development center at Texas Children’s Hospital.

According to a CNBC analysis of the Johns Hopkins data, the average daily cases of coronavirus in the United States have decreased by about 57%. However, some states don’t see such a sharp decline. Vermont is only down 22% averaging daily falls, New York is down about 45%, Oregon is down nearly 47%, and Florida is down 48% averaging daily. Hotez recognized Florida for distributing a highly transmissible variant of Covid in the state, which was first found in the UK

“The only state that really intrigues me, not necessarily in a good way, is Florida because we hear that about 10% of Florida-derived virus isolates are the UK-derived B.117 variant.” said Hotez in an interview on Wednesday night.

Hotez urged that now is the time for the US to really take a vaccination boost, especially before more variants of Covid spread. While AstraZeneca reported that it expects its vaccine to be approved in the US in April, Hotez said, “I think sometimes we have to think about making the beep” and should approve it sooner.

Categories
Health

Moderna to start trials of Covid vaccine booster photographs for variant from South Africa

NY will begin offering shots to people with underlying health conditions this month

A health care worker gives a picture of Moderna COVID-19 to a woman at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in New York on January 29, 2021 Vaccine.

Facebook Facebook Logo Log in to Facebook to connect with Mike Segar Reuters

Moderna announced on Wednesday that a new Covid-19 vaccine, which is said to offer better protection against the highly contagious variant of coronavirus that is widespread in South Africa, has been delivered to the National Institutes of Health.

The vaccine – which Moderna names mRNA-1273.351 – can be tested in an early clinical trial to see if it can be used as a booster against the South African strain, also known as B.1.351. Moderna has found that its current two-dose regimen produces a weaker immune response against the South African strain, although the company said the antibodies in patients remain above levels expected to protect against the virus.

“Moderna is committed to making as many updates as necessary to our vaccine until the pandemic is under control,” said the company’s CEO, Stephane Bancel, in a press release. “We hope to show that booster doses can be given at lower doses when needed, which will allow us to make many more doses available to the global community when needed in late 2021 and 2022.”

US health officials are increasingly concerned about new, emerging variants of the virus, particularly strain B.1.351, which has been shown to reduce the effectiveness of vaccines both in market and in development. Over the past few weeks, the White House Chief Medical Officer, Dr. Anthony Fauci, urged Americans to get vaccinated as soon as possible before potentially new and even more dangerous variants of the virus emerge.

As of Tuesday, the Centers for Disease Control and Prevention had identified 1,881 cases of variant B.1.1.7, which were first found in the UK. The US authorities said they had identified 46 cases of the strain B.1.351 from South Africa and five cases of P.1, a variant first discovered in Brazil. The more people become infected, the more likely it is that even more problematic mutations will occur, say medical experts.

On Monday, the Food and Drug Administration released updated guidelines that modified Covid-19 vaccines that work to protect against new, emerging variants may be approved without the need for lengthy clinical trials. The FDA would approve the new vaccine as an amendment to a company’s originally approved emergency filing, thereby expediting the regulatory review process.

Moderna first announced on January 25 that it was working on a booster shot to protect itself against the variant in South Africa.

The company announced on Wednesday that it is evaluating three approaches to increasing immunity. The first approach would use variant-specific booster vaccinations such as mRNA-1273.351, but at a lower dose than the original vaccine. The second would combine the original vaccine with a variant-specific vaccine into a single shot at 50 micrograms or less, Moderna said. The third would test a third shot of the original vaccine at a lower dose.

Moderna said it also plans to test the original vaccine and new booster shot as a two-dose regimen in people without coronavirus antibodies.

Separately, the company also announced that it is expected to produce up to 1.4 billion doses of Covid-19 vaccine by 2022. It has also raised its global base production estimate from 600 million cans to 700 million cans this year.

According to Moderna, the 1.4 billion doses in 2022 assume the vaccine will be given at its current level of 100 micrograms. If the vaccine turns out to be effective at a lower dose, the company could deliver up to 2.8 billion doses by 2022, the company said.

Moderna has signed a contract with the US government for 300 million cans. The company has shipped around 55 million cans to the US to date. The first 100 million cans are expected to be shipped to the US by the end of the first quarter of 2021, the second 100 million cans by the end of May 2021, and the third 100 million cans by the end of July 2021.